Drugs News and Research

RSS

Mouse model of ALS closely resembles humans with the paralyzing disorder, says report

A new mouse model of amyotrophic lateral sclerosis (ALS) closely resembles humans with the paralyzing disorder, researchers at Washington University School of Medicine in St. Louis report.

13 Oct 2009

Thomson Reuters's NeoFax deployed at the University of Kansas Hospital for electronic neonatal drug dosing

The University of Kansas Hospital has deployed NeoFax(®) from Thomson Reuters to provide physicians, nurses, and pharmacy staff in its neonatal intensive care unit with electronic drug dosing, interaction checking, and reference information.

13 Oct 2009

Debiopharm Group and Ipsen complete European decentralised registration of Decapeptyl

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group, announced that the 6-month sustained-release formulation of Decapeptyl®1 (triptorelin embonate2 22.5 mg) successfully completed its European decentralised registration procedure involving nine countries: Germany (reference member state), France, Austria, Finland, Norway, Belgium, Denmark, Spain and The Netherlands.

13 Oct 2009

Kidney Care Partners commends CBC for supporting reforms to improve access to quality kidney care

Kidney Care Partners - an alliance of patient advocates, dialysis professionals, care providers and manufacturers working together to improve quality of care for individuals with kidney disease and kidney failure - today applauded the Congressional Black Caucus (CBC) for supporting reforms that will improve patient access and choice in receiving quality kidney care.

13 Oct 2009

Acupuncture can help prevent caesarean delivery

Debra Betts, an international expert, educator and author of the Essential Acupuncture for Pregnancy and Childbirth will be presenting a workshop for dulas, midwives and acupuncturists in Vancouver, October 13th and 14th.

13 Oct 2009

Legendary coach helps raise awareness on osteoarthritis

After leading the U.S. men’s basketball team to Olympic gold last year and two weeks before the start of his 30th season as head coach of Duke University’s men’s basketball team, Mike Krzyzewski (Coach K), 61, is teaming up with the Arthritis Foundation to help raise awareness of the disease that nearly ended his coaching career 10 years ago.

13 Oct 2009

Health care reform should include transparency requirements for PBMs: Consumer groups

More than 30 groups representing consumer, labor and Medicare beneficiaries have joined a growing coalition urging Congress to support transparency requirements for pharmacy benefit managers (PBMs) in the health care reform proposals being considered by Congress.

13 Oct 2009

H1N1 illness in young Mexican patients associated with severe acute respiratory distress syndrome

Critical illness from 2009 influenza A(H1N1) in Mexico occurred among young patients, was associated with severe acute respiratory distress syndrome and shock, and had a fatality rate of about 40 percent, according to a study to appear in the November 4 issue of JAMA.

12 Oct 2009

Health Robotics' i.v.STATION robot wins the Area Science Park 3L 3T Innovation Award

Health Robotics today announced the manufacturing, shipment, and subsequent field installation of the first five i.v.STATION post-prototype robots in the United States of America and in Spain within the September to November timeframe this year; concurrently, Health Robotics also made the announcement of its i.v.STATION robot's winning of the Area Science Park 3L 3T Innovation Award, which is given to the best technology product across all industries.

12 Oct 2009

Benefits of health overhaul won't be immediate

Mechanisms to make health insurance more affordable for families and low- and middle-income households won't start until 2013 if health care reform passes.

12 Oct 2009

QRxPharma signs contractual agreement with Patheon

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today a contractual agreement with Patheon to manufacture clinical supplies of QRxPharma's controlled release Dual-Opioid(TM) formulation (MoxDuo(TM)CR). MoxDuo(TM)CR is designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic).

12 Oct 2009

Employers offering more high-deductible plans this enrollment season

When open enrollment rolls around again this year, workers may be faced with more health insurance choices: "more employers may include a new type of plan that can chop premium payments by nearly 20 percent and give consumers a tax break," The Associated Press reports.

12 Oct 2009

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O’Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.

12 Oct 2009

Wake Forest University School of Medicine honours researchers

Wake Forest University School of Medicine honored eight of its researchers with awards for excellence at the 13th Annual Research Awards Day Oct. 1.

12 Oct 2009

NOXXON Pharma announces the successful completion of the first phase I trial of Spiegelmer NOX-E36

NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, today announced successful completion of the first phase I trial with its anti-inflammatory Spiegelmer® NOX-E36. This drug candidate will be developed for the treatment of complications of type 2 diabetes, preferentially diabetic nephropathy, but also others.

12 Oct 2009

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Heptares Therapeutics Ltd, the drug discovery company focused on G-protein-coupled receptor (GPCR) targets, announced today that it has entered into an option agreement with the Novartis Option Fund under which Heptares will apply its proprietary StaR(TM) technology to generate novel drug leads against a nominated, unspecified GPCR target of interest to Novartis.

12 Oct 2009

Compounds that bock nutrient-sensing receptor may impact obesity and diabetic conditions

According to new research from the Monell Center and the Mount Sinai School of Medicine, certain common herbicides and lipid-lowering fibrate drugs act in humans to block T1R3, a nutrient-sensing taste receptor also present in intestine and pancreas.

12 Oct 2009

Researchers find how KEAP1 tumor suppressor works

A tumor-suppressing protein snatches up an important cancer-promoting enzyme and tags it with molecules that condemn it to destruction, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports this week in the journal Molecular Cell.

12 Oct 2009

Detroit jury indicts alleged perpetrators of X-Press Center $2.3M Medicare fraud scheme

Three Miami-Dade County, Fla., residents have been indicted in connection with an alleged $2.3 million Medicare fraud scheme operated out of X-Press Center, a Detroit-area clinic that purported to specialize in providing injection and infusion therapies, Assistant Attorney General of the Criminal Division Lanny A. Breuer, U.S. Attorney for the Eastern District of Michigan Terrence Berg and Daniel R. Levinson, Inspector General of the Department of Health & Human Services (HHS) announced today.

12 Oct 2009

New technique may lead to more effective treatment for liver disease

A combination of bioengineering and medical research at the University of California, San Diego has led to a new discovery that could pave the way for more effective treatments for liver disease.

12 Oct 2009

Drugs News and Research

Mouse model of ALS closely resembles humans with the paralyzing disorder, says report

Thomson Reuters's NeoFax deployed at the University of Kansas Hospital for electronic neonatal drug dosing

Debiopharm Group and Ipsen complete European decentralised registration of Decapeptyl

Kidney Care Partners commends CBC for supporting reforms to improve access to quality kidney care

Acupuncture can help prevent caesarean delivery

Legendary coach helps raise awareness on osteoarthritis

Health care reform should include transparency requirements for PBMs: Consumer groups

H1N1 illness in young Mexican patients associated with severe acute respiratory distress syndrome

Health Robotics' i.v.STATION robot wins the Area Science Park 3L 3T Innovation Award

Benefits of health overhaul won't be immediate

QRxPharma signs contractual agreement with Patheon

Employers offering more high-deductible plans this enrollment season

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Wake Forest University School of Medicine honours researchers

NOXXON Pharma announces the successful completion of the first phase I trial of Spiegelmer NOX-E36

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Compounds that bock nutrient-sensing receptor may impact obesity and diabetic conditions

Researchers find how KEAP1 tumor suppressor works

Detroit jury indicts alleged perpetrators of X-Press Center $2.3M Medicare fraud scheme

New technique may lead to more effective treatment for liver disease

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News